Effects of Type 2 Diabetes Mellitus on Osteoclast Differentiation, Activity, and Cortical Bone Formation in POSTmenopausal MRONJ Patients

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 May 14

PMID 35566506

Authors

Sung-Min Park

Jae-Hoon Lee

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a common metabolic bone disease in patients with diabetes, which can develop simultaneously with type 2 diabetes (T2D) in postmenopausal women. Bisphosphonate (BP) is administered to patients with both conditions and may cause medication-related osteonecrosis of the jaw (MRONJ). It affects the differentiation and function of osteoclasts as well as the thickness of the cortical bone through bone mineralization. Therefore, this study aimed to investigate the effects of T2D on osteoclast differentiation and activity as well as cortical bone formation in postmenopausal patients with MRONJ. Tissue samples were collected from 10 patients diagnosed with T2D and stage III MRONJ in the experimental group and from 10 patients without T2D in the control group. A histological examination was conducted, and the expression of dendritic cell-specific transmembrane protein (DC-STAMP) and tartrate-resistant acid phosphatase (TRAP) was assessed. Cortical bone formation was analyzed using CBCT images. The number of TRAP-positive osteoclasts and DC-STAMP-positive mononuclear cells was significantly less in the experimental group (p < 0.05). Furthermore, the thickness and ratio of cortical bone were significantly greater in the experimental group (p < 0.05). In conclusion, T2D decreased the differentiation and function of osteoclasts and increased cortical bone formation in postmenopausal patients with MRONJ.

Citing Articles

A blood glucose fluctuation-responsive delivery system promotes bone regeneration and the repair function of Smpd3-reprogrammed BMSC-derived exosomes.

Wang L, Yang H, Zhang C, Zhang Y, He Y, Liu Y Int J Oral Sci. 2024; 16(1):65.

PMID: 39616150 PMC: 11608271. DOI: 10.1038/s41368-024-00328-6.

Platelet-Rich Fibrin Treatment Evaluation in Patients with Medication-Related Osteonecrosis of the Jaw and Osteoradionecrosis.

Roman R, Moldovan M, Pop L, Megiesan S, Faur C J Clin Med. 2024; 13(12).

PMID: 38930013 PMC: 11204677. DOI: 10.3390/jcm13123473.

Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid.

Ciobanu G, Mogoanta L, Popescu S, Ionescu M, Munteanu C, Staicu I Int J Mol Sci. 2023; 24(18).

PMID: 37762651 PMC: 10532296. DOI: 10.3390/ijms241814345.

Association between Hyperglycemia and Medication-Related Osteonecrosis of the Jaw (MRONJ).

Kammerhofer G, Vegh D, Banyai D, Vegh A, Joob-Fancsaly A, Hermann P J Clin Med. 2023; 12(8).

PMID: 37109314 PMC: 10144577. DOI: 10.3390/jcm12082976.

References

Kirstein B, Chambers T, Fuller K . Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem. 2006; 98(5):1085-94. DOI: 10.1002/jcb.20835. View

Botolin S, McCabe L . Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006; 99(2):411-24. DOI: 10.1002/jcb.20842. View

Karsdal M, Martin T, Bollerslev J, Christiansen C, Henriksen K . Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res. 2007; 22(4):487-94. DOI: 10.1359/jbmr.070109. View

Torres S, Chen C, Leroux B, Lee P, Hollender L, Santos E . Mandibular cortical bone evaluation on cone beam computed tomography images of patients with bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113(5):695-703. DOI: 10.1016/j.oooo.2011.11.011. View

Seeman E . Bone morphology in response to alendronate as seen by high-resolution computed tomography: Through a glass darkly. J Bone Miner Res. 2010; 25(12):2553-7. DOI: 10.1002/jbmr.261. View

Melton 3rd L, Leibson C, Achenbach S, Therneau T, Khosla S . Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008; 23(8):1334-42. PMC: 2574704. DOI: 10.1359/jbmr.080323. View

Feng X, McDonald J . Disorders of bone remodeling. Annu Rev Pathol. 2010; 6:121-45. PMC: 3571087. DOI: 10.1146/annurev-pathol-011110-130203. View

Farr J, Drake M, Amin S, Melton 3rd L, McCready L, Khosla S . In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2013; 29(4):787-95. PMC: 3961509. DOI: 10.1002/jbmr.2106. View

Dede A, Tournis S, Dontas I, Trovas G . Type 2 diabetes mellitus and fracture risk. Metabolism. 2014; 63(12):1480-90. DOI: 10.1016/j.metabol.2014.09.002. View

10.

Burr D, Miller L, Grynpas M, Li J, Boyde A, Mashiba T . Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone. 2003; 33(6):960-9. DOI: 10.1016/j.bone.2003.08.004. View

11.

Janghorbani M, van Dam R, Willett W, Hu F . Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5):495-505. DOI: 10.1093/aje/kwm106. View

12.

Chiu Y, Mensah K, Schwarz E, Ju Y, Takahata M, Feng C . Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. 2011; 27(1):79-92. PMC: 3304467. DOI: 10.1002/jbmr.531. View

13.

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

14.

Leslie W, Lix L, Prior H, Derksen S, Metge C, ONeil J . Biphasic fracture risk in diabetes: a population-based study. Bone. 2007; 40(6):1595-601. DOI: 10.1016/j.bone.2007.02.021. View

15.

Bonds D, Larson J, Schwartz A, Strotmeyer E, Robbins J, Rodriguez B . Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006; 91(9):3404-10. DOI: 10.1210/jc.2006-0614. View

16.

Hayman A, Jones S, Boyde A, Foster D, Colledge W, Carlton M . Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development. 1996; 122(10):3151-62. DOI: 10.1242/dev.122.10.3151. View

17.

Koo C, Lee J . Evaluation of mandibular cortical bone ratio on computed tomography images in patients taking bisphosphonates. Maxillofac Plast Reconstr Surg. 2018; 40(1):17. PMC: 6031557. DOI: 10.1186/s40902-018-0153-5. View

18.

Paschou S, Dede A, Anagnostis P, Vryonidou A, Morganstein D, Goulis D . Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017; 102(10):3621-3634. DOI: 10.1210/jc.2017-00042. View

19.

Gross C, Weber M, Creutzburg K, Mobius P, Preidl R, Amann K . Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis. J Transl Med. 2017; 15(1):128. PMC: 5461625. DOI: 10.1186/s12967-017-1230-8. View

20.

Weinstein R, Roberson P, Manolagas S . Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360(1):53-62. PMC: 2866022. DOI: 10.1056/NEJMoa0802633. View